Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Clinical significance of protocadherin-8 (PCDH8) promoter methylation in bladder cancer.

Lin YL, Ma JH, Luo XL, Guan TY, Li ZG.

J Int Med Res. 2013 Feb;41(1):48-54. doi: 10.1177/0300060513475571. Epub 2013 Jan 23. Erratum in: J Int Med Res. 2014 Oct;42(5):1189. Retraction in: J Int Med Res. 2014 Oct;42(5):1189.

PMID:
23569129
2.

Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.

Lin YL, Wang YL, Ma JG, Li WP.

J Exp Clin Cancer Res. 2014 Aug 22;33:68. doi: 10.1186/s13046-014-0068-7.

3.

Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer.

Luo ZG, Li ZG, Gui SL, Chi BJ, Ma JG.

J Int Med Res. 2014 Feb;42(1):35-41. doi: 10.1177/0300060513504705. Epub 2013 Dec 23.

PMID:
24366498
4.

Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma.

Wang XB, Lin YL, Li ZG, Ma JH, Li J, Ma JG.

J Int Med Res. 2014 Apr;42(2):292-9. doi: 10.1177/0300060513504364. Epub 2014 Feb 24.

PMID:
24567353
5.

Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer.

Lin YL, Li ZG, He ZK, Guan TY, Ma JG.

J Int Med Res. 2012;40(6):2117-23.

PMID:
23321168
6.

Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma.

Lin YL, Liu XQ, Li WP, Sun G, Zhang CT.

Int Urol Nephrol. 2012 Feb;44(1):111-7. doi: 10.1007/s11255-011-9961-6. Epub 2011 Apr 24.

PMID:
21516472
7.
8.

The clinical significance of PCDH10 promoter methylation in patients with bladder transitional cell carcinoma.

Lin YL, Li ZG, Guan TY.

Urol Int. 2013;90(2):219-24. doi: 10.1159/000345053. Epub 2012 Nov 16.

PMID:
23171734
9.
10.

Frequent silencing of protocadherin 8 by promoter methylation, a candidate tumor suppressor for human gastric cancer.

Zhang D, Zhao W, Liao X, Bi T, Li H, Che X.

Oncol Rep. 2012 Nov;28(5):1785-91. doi: 10.3892/or.2012.1997. Epub 2012 Aug 30.

PMID:
22941331
11.

RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.

Yan C, Kim YW, Ha YS, Kim IY, Kim YJ, Yun SJ, Moon SK, Bae SC, Kim WJ.

J Surg Oncol. 2012 Mar 15;105(4):425-30. doi: 10.1002/jso.22087. Epub 2011 Aug 30.

PMID:
22311819
12.

Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.

Kim JS, Chae Y, Ha YS, Kim IY, Byun SS, Yun SJ, Kim WJ.

Clin Genitourin Cancer. 2012 Jun;10(2):114-20. doi: 10.1016/j.clgc.2011.12.003. Epub 2012 Feb 28.

PMID:
22382007
13.

Hypermethylation of E-cadherin, p16, p14, and RASSF1A genes in pathologically normal urothelium predict bladder recurrence of bladder cancer after transurethral resection.

Lin HH, Ke HL, Wu WJ, Lee YH, Chang LL.

Urol Oncol. 2012 Mar-Apr;30(2):177-81. doi: 10.1016/j.urolonc.2010.01.002. Epub 2010 Aug 25.

PMID:
20800513
14.

Aberrant methylation of PCDH8 is a potential prognostic biomarker for patients with clear cell renal cell carcinoma.

Lin YL, Wang YL, Fu XL, Ma JG.

Med Sci Monit. 2014 Nov 22;20:2380-5. doi: 10.12659/MSM.892433.

15.

Downregulation of protocadherin-10 expression correlates with malignant behaviour and poor prognosis in human bladder cancer.

Ma JG, He ZK, Ma JH, Li WP, Sun G.

J Int Med Res. 2013 Feb;41(1):38-47. doi: 10.1177/0300060513476989. Epub 2013 Jan 23.

PMID:
23569128
16.

Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.

Harada H, Miyamoto K, Yamashita Y, Taniyama K, Mihara K, Nishimura M, Okada M.

Cancer Med. 2015 Oct;4(10):1536-46. doi: 10.1002/cam4.507. Epub 2015 Aug 15.

17.

Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1.

Heitzer E, Artl M, Filipits M, Resel M, Graf R, Weißenbacher B, Lax S, Gnant M, Wrba F, Greil R, Dietze O, Hofbauer F, Böhm G, Höfler G, Samonigg H, Schaberl-Moser R, Balic M, Dandachi N.

Mod Pathol. 2014 Jun;27(6):906-15. doi: 10.1038/modpathol.2013.204. Epub 2013 Dec 6.

18.

Promoter methylation of protocadherin8 is an independent prognostic factor for biochemical recurrence of early-stage prostate cancer.

Niu WB, Gui SL, Lin YL, Fu XL, Ma JG, Li WP.

Med Sci Monit. 2014 Dec 8;20:2584-9. doi: 10.12659/MSM.893083.

19.

Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.

Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, Van Criekinge W, Westra WH, Schoenberg M, Zahurak M, Goodman SN, Sidransky D.

J Natl Cancer Inst. 2006 Jul 19;98(14):996-1004.

PMID:
16849682
20.

Frequency of P16INK4a and P14ARF genes methylation and its impact on bladder cancer cases in north Indian population.

Ali Hosseini S, Sobti RC, Malekzadeh K, Singh SK, Joshi K.

Dis Markers. 2010;28(6):361-8. doi: 10.3233/DMA-2010-0716.

Supplemental Content

Support Center